Author Affiliations: Departments of Medicine, Cell-Developmental Biology and Cancer Biology, The Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tenn.
In this issue of THE JOURNAL, Terry et al1 report
that aspirin use in women is associated with a significant reduction in the
risk of breast cancer, especially for hormone receptor–positive tumors.
Previous studies have examined the relationship between breast cancer risk
and aspirin or other nonsteroidal anti-inflammatory drug (NSAID) use but have
not delineated different subtypes of breast cancers to determine this kind
of correlation. This report is the first to examine whether the protective
effect of aspirin varies with estrogen receptor (ER) or progesterone receptor
(PR) status. With the genomic and proteomic revolution well underway, it is
becoming quite clear that there are distinct differences in molecular signatures
between tumors derived from the same organ. It is well known that the hormonal
responsiveness of breast cancers is important for determining the treatment
regimen and can affect the clinical outcome. Thus, it is not surprising that
one subset of breast cancers may be more responsive to a particular prevention
strategy than another.
DuBois RN. Aspirin and Breast Cancer PreventionThe Estrogen Connection. JAMA. 2004;291(20):2488-2489. doi:10.1001/jama.291.20.2488